LEXEO Therapeutics Strengthens Management Team with Key Appointments LEXEO strengthens management team with key appointments to accelerate development of clinical-stage pipeline.
LEXEO Therapeutics Announces License Agreement and Consolidation of Pre-clinical Data Package Lexeo completes license of all intellectual property rights and pre-clinical data associated with Adverum's Friedreich's ataxia program.
LEXEO Therapeutics Launches with $85 Million Series A Financing to Develop Gene Therapies LEXEO Therapeutics, a fully integrated gene therapy company, launches with financing from Longitude Capital and Omega Funds.
Dec 16, 2020Human Gene TherapyPositron emission tomography (PET) images 24 hr after administration of I-124 labeled AAVrh10 by the intracisternal route to a nonhuman...
Dec 2, 2020Slowing Late Infantile Batten Disease Late infantile Batten disease (CLN2 disease) is an autosomal recessive, neurodegenerative lysosomal storage disease caused by mutations...
